Meningococcal group A, C, Y and W-135 conjugate vaccine
- PMID: 20514064
- DOI: 10.1038/nrd3194
Meningococcal group A, C, Y and W-135 conjugate vaccine
Abstract
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11-55 years.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
